Subpopulations of uPAR+ contribute to vasculogenic mimicry and metastasis in large cell lung cancer

Experimental and Molecular Pathology

Volumn 98, Issue 2, 2015, Pages 136-144

  Li, Yanlei ^a   Sun, Baocun ^a   Zhao, Xiulan ^a   Zhang, Danfang ^a   Wang, Xudong ^a   Zhu, Dongwang ^a   Yang, Zhihong ^a   Qiu, Zhiqiang ^a   Ban, Xinchao ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Hospital   (China)

Author keywords

Large cell lung cancer; Metastasis; UPAR; Vasculogenic mimicry

Indexed keywords

CADHERIN; LEUKOCYTE ANTIGEN; NUCLEAR PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN; UROKINASE RECEPTOR; VASCULAR ENDOTHELIAL CADHERIN; VIMENTIN;

ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; LARGE CELL CARCINOMA; LIVER TUMOR; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE; TUMOR INVASION; VERY ELDERLY; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; CADHERINS; CARCINOMA, LARGE CELL; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TWIST TRANSCRIPTION FACTOR; VIMENTIN;

EID: 84924407898     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.02.001     Document Type: Article

References (42)

1. Andreasen P.A., et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72:1-22.
2. Battafarano R.J., et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2005, 130:166-172.
3. Cao Z., et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur. J. Cancer 2013, 49:3914-3923.
4. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
5. Cheng X., et al. ECRG2 regulates ECM degradation and uPAR/FPRL1 pathway contributing cell invasion/migration. Cancer Lett. 2010, 290:87-95.
6. Czekay R.P., et al. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 2001, 12:1467-1479.
7. Daneri-Navarro A., et al. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur. J. Cancer 1998, 34:566-569.
8. Dome B., et al. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am. J. Pathol. 2007, 170:1-15.
9. Fan Y.L., et al. A new perspective of vasculogenic mimicry: EMT and cancer stem cells (review). Oncol. Lett. 2013, 6:1174-1180.
10. Fernandez F.G., Battafarano R.J. Large-cell neuroendocrine carcinoma of the lung. Cancer Control 2006, 13:270-275.
11. Ferraris G.M., et al. The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins. EMBO J. 2014, 33:2458-2472.
12. Gao Y., et al. Correlation of vasculogenic mimicry with clinicopathologic features and prognosis of ovarian carcinoma. Zhonghua Bing Li Xue Za Zhi 2009, 38:585-589.
13. Gondi C.S., et al. Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol. 2004, 1:165-176.
14. Goossens S., et al. The EMT regulator Zeb2/Sip1 is essential for murine embryonic hematopoietic stem/progenitor cell differentiation and mobilization. Blood 2011, 117:5620-5630.
15. Gupta R., et al. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int. J. Oncol. 2011, 38:733-744.
16. Halamkova J., et al. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 2011, 58:1918-1925.
17. Hao X.S., et al. Correlation between the expression of collagen IV, VEGF and vasculogenic mimicry. Zhonghua Zhong Liu Za Zhi 2003, 25:524-526.
18. Hendrix M.J., et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8018-8023.
19. Henic E., et al. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Int. J. Gynecol. Cancer 2009, 19:214-222.
20. Hu Z., et al. GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway. Exp. Cell Res. 2013, 319:1932-1941.
21. + melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 2012, 72:5111-5118.
22. Li Y., et al. Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. Int. J. Clin. Exp. Pathol. 2014, 7:3771-3780.
23. Liu R., et al. Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol. Ther. 2012, 13:527-533.
24. + cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 2013, 32:544-553.
25. Madsen C.D., et al. uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 2007, 177:927-939.
26. Maniotis A.J., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999, 155:739-752.
27. Montuori N., Ragno P. Role of uPA/uPAR in the modulation of angiogenesis. Chem. Immunol. Allergy 2014, 99:105-122.
28. Ombrato L., Malanchi I. The EMT universe: space between cancer cell dissemination and metastasis initiation. Crit. Rev. Oncog. 2014, 19:349-361.
29. Qiu X., et al. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett. 2012, 323:161-170.
30. Rao J.S., et al. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol. Cancer Ther. 2005, 4:1399-1408.
31. Seftor R.E., et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001, 61:6322-6327.
32. Seftor R.E., et al. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol. Cancer Ther. 2002, 1:1173-1179.
33. Shirakawa K., et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int. J. Cancer 2002, 99:821-828.
34. Sun T., et al. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 2011, 54:1690-1706.
35. Tang D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012, 22:457-472.
36. Tang H.S., et al. Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int. J. Gynecol. Cancer 2009, 19:605-610.
37. Uhrin P., Breuss J.M. uPAR: a modulator of VEGF-induced angiogenesis. Cell Adhes. Migr. 2013, 7:23-26.
38. Volm M., et al. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol. Rep. 1999, 6:611-615.
39. Wu S., et al. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry. J. Huazhong Univ. Sci. Technol. Med. Sci. 2012, 32:346-352.
40. Ye C.J., et al. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J. Cell. Physiol. 2009, 219:288-300.
41. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
42. Zhang Y., et al. Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J. Surg. Oncol. 2013, 108:414-419.